EFC12522 IMROZ
A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with
newly diagnosed multiple myeloma not eligible for transplant.
Detalhes
Destaques